Det primære mål for effekt var en 20% forbedring i responskriterier i Assessment in Ankylosing Spondylitis (ASAS 20).
The primary measure of efficacy (ASAS 20) was a  20% improvement in at least 3 of the 4 Assessment in Ankylosing Spondylitis (ASAS) domains (patient global assessments, back pain, BASFI, and inflammation) and absence of deterioration in the remaining domain.